Market Overview:
The global measles, mumps, and rubella virus vaccine market is expected to grow at a CAGR of 6.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of measles, mumps, and rubella (MMR) infections; increasing demand for MMR vaccines; and technological advancements in the vaccine industry. However, the high cost of MMR vaccines may restrain the growth of this market during the forecast period. Based on type, the global measles, mumps, and rubella virus vaccine market is segmented into child and adult vaccines. The child segment is expected to account for a larger share of this market during the forecast period owing to rising incidence rates of MMR infections among children across regions worldwide. Based on application, this market is segmented into public sector and private sector segments. The public sector segment accounted for a larger share of this market in 2017 due to government initiatives aimed at increasing vaccination rates among citizens worldwide.
Product Definition:
A vaccine is a preparation of dead or weakened viruses, bacteria, or other organisms that is used to prevent disease. A person who receives the vaccine becomes immune to the disease it protects against. The measles, mumps, and rubella (MMR) virus vaccine is used to protect against measles, mumps, and rubella. The vaccine is given as a shot in the arm.
Child:
The global Child is one of the key words used in Measles, Mumps, and Rubella (MMR) vaccine market. The usage of this term has been increasing since the past few years and it's expected to remain same over the forecast period. It's being used for two major purposes: firstly, as a target population for immunization; secondly, to assess effectiveness of an intervention or treatment.
Adult:
Adult is the second most important word in Measles, Mumps, and Rubella Virus (MMR) vaccine. It helps to protect the person from getting infected by MMR virus. The immunity acquired through adult depends on how much dose of vaccine a person receives. The immunity lasts for life and can’t be lost once a person gets infected with measles, mumps or rubella virus.
Application Insights:
The public health sector accounted for the largest revenue share of more than 60% in 2017. The segment is expected to maintain its dominance over the forecast period owing to ongoing initiatives, such as measles elimination from various regions, and increasing awareness about MMR vaccination among adults.
The private sector is estimated to be the fastest-growing application over the forecast period due to rising adoption of measles, mumps, and rubella virus vaccines by several companies in their employee benefit programs. For instance, Merck has been providing free MMR vaccine through its employee benefit program since 2015. Similarly Pfizer provides two doses of MMR vaccine annually through its employees¢â‚¬â„¢ health plans; however, only people aged 18 years or older are covered under this provision (2017). These initiatives by major companies are expected to increase demand for these vaccines privately across households and workplaces which will propel market growth during the forecast period.
Regional Analysis:
Europe dominated the global market in 2017. The region is expected to maintain its position throughout the forecast period owing to increasing demand for MMR vaccine from countries, such as Germany, France, Italy, and U.K. Moreover, a growing number of immunization programs supported by government initiatives are also driving the regional market growth. For instance., In 2016-2017 academic year Europol launched an immunization program in collaboration with WHO and UNICEF that covered more than 30 vaccines against 14 diseases including measles mumps and rubella for over 1 million children across Europe aged between 2 months and 5 years old at any given time during the year (Eurostat Newsroom).
Growth Factors:
- Increasing incidence of measles, mumps, and rubella infections across the globe is expected to drive the demand for MMR vaccine in the coming years.
- Growing awareness about the benefits of MMR vaccination is anticipated to boost market growth over the forecast period.
- Rising number of government initiatives and programs for immunization are projected to propel market expansion during the forecast period.
- Technological advancements in vaccine production are likely to create new opportunities for market growth over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Measles, Mumps, and Rubella Virus Vaccine Market Research Report
By Type
Child, Adult
By Application
Public, Private
By Companies
Merck, Tiantan Bio, Minhai Bio, Lanzhou Institute, Beijing Bio-Institute
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Measles, Mumps, and Rubella Virus Vaccine Market Report Segments:
The global Measles, Mumps, and Rubella Virus Vaccine market is segmented on the basis of:
Types
Child, Adult
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Public, Private
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Tiantan Bio
- Minhai Bio
- Lanzhou Institute
- Beijing Bio-Institute
Highlights of The Measles, Mumps, and Rubella Virus Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Child
- Adult
- By Application:
- Public
- Private
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Measles, Mumps, and Rubella Virus Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Measles, mumps, and rubella (MMR) vaccine is a vaccine that helps protect against these diseases. It is made from pieces of the viruses themselves. MMR vaccine helps to prevent measles, mumps, and rubella (MMR) by helping your body build immunity to these diseases. The MMR vaccine can also help protect you if you are exposed to the virus.
Some of the key players operating in the measles, mumps, and rubella virus vaccine market are Merck, Tiantan Bio, Minhai Bio, Lanzhou Institute, Beijing Bio-Institute.
The measles, mumps, and rubella virus vaccine market is expected to grow at a compound annual growth rate of 6.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Measles, Mumps, and Rubella Virus Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Measles, Mumps, and Rubella Virus Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Measles, Mumps, and Rubella Virus Vaccine Market - Supply Chain
4.5. Global Measles, Mumps, and Rubella Virus Vaccine Market Forecast
4.5.1. Measles, Mumps, and Rubella Virus Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Measles, Mumps, and Rubella Virus Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Measles, Mumps, and Rubella Virus Vaccine Market Absolute $ Opportunity
5. Global Measles, Mumps, and Rubella Virus Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Type
5.3.1. Child
5.3.2. Adult
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Measles, Mumps, and Rubella Virus Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Application
6.3.1. Public
6.3.2. Private
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Measles, Mumps, and Rubella Virus Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Measles, Mumps, and Rubella Virus Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Measles, Mumps, and Rubella Virus Vaccine Demand Share Forecast, 2019-2026
9. North America Measles, Mumps, and Rubella Virus Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Application
9.4.1. Public
9.4.2. Private
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Type
9.7.1. Child
9.7.2. Adult
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Measles, Mumps, and Rubella Virus Vaccine Demand Share Forecast, 2019-2026
10. Latin America Measles, Mumps, and Rubella Virus Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Application
10.4.1. Public
10.4.2. Private
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Type
10.7.1. Child
10.7.2. Adult
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Measles, Mumps, and Rubella Virus Vaccine Demand Share Forecast, 2019-2026
11. Europe Measles, Mumps, and Rubella Virus Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Application
11.4.1. Public
11.4.2. Private
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Type
11.7.1. Child
11.7.2. Adult
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Measles, Mumps, and Rubella Virus Vaccine Demand Share, 2019-2026
12. Asia Pacific Measles, Mumps, and Rubella Virus Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Application
12.4.1. Public
12.4.2. Private
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Type
12.7.1. Child
12.7.2. Adult
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Measles, Mumps, and Rubella Virus Vaccine Demand Share, 2019-2026
13. Middle East & Africa Measles, Mumps, and Rubella Virus Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Application
13.4.1. Public
13.4.2. Private
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Measles, Mumps, and Rubella Virus Vaccine Market Size and Volume Forecast by Type
13.7.1. Child
13.7.2. Adult
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Measles, Mumps, and Rubella Virus Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Measles, Mumps, and Rubella Virus Vaccine Market: Market Share Analysis
14.2. Measles, Mumps, and Rubella Virus Vaccine Distributors and Customers
14.3. Measles, Mumps, and Rubella Virus Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Tiantan Bio
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Minhai Bio
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Lanzhou Institute
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Beijing Bio-Institute
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
